Pfizer is inviting interested individuals to apply to participate in an “elevator pitch” session to be held on the 25th September in London. This will form part of the Pfizer Rare Disease Consortium (RDC) Inaugural Symposium, which will be a prestigious event bringing together senior leaders across academia and Pfizer. The call area is “future rare disease therapies”, covering any disease area within the rare disease spectrum (although applications in core themes of haematology, neuromuscular, pulmonary and cardiac would be preferred). Applicants would be requested to “pitch” their idea in a 3 minute slot (without slides) followed by a short Q&A with immediate feedback from a panel. Interested applicants should contact Vjera Magdalenic-Moussavi on v.magdalenic@imperial.ac.uk by the deadline of 1st August.
About RDC: The Rare Disease Consortium is an agreement between Pfizer and GMEC which provides scientists from the GMEC partners – Cambridge University, Imperial College London, King’s College London, Queen Mary University London, University College London and Oxford University – the opportunity to work with Pfizer scientists on joint drug discovery programmes. Bringing together the scientific and clinical excellence of the Universities and Academic Health Science Centres in the GMEC cluster with the drug discovery and development skills of Pfizer has the potential to accelerate the translation of basic science into a new generation of innovative medicines for the treatment of these debilitating and life-threatening conditions.
Dr Vjera Magdalenic-Moussavi
Corporate and Enterprise Partnerships Manager
Faculty of Medicine